CN115671132A - Composition of probiotics and prebiotics and application thereof - Google Patents
Composition of probiotics and prebiotics and application thereof Download PDFInfo
- Publication number
- CN115671132A CN115671132A CN202211459787.9A CN202211459787A CN115671132A CN 115671132 A CN115671132 A CN 115671132A CN 202211459787 A CN202211459787 A CN 202211459787A CN 115671132 A CN115671132 A CN 115671132A
- Authority
- CN
- China
- Prior art keywords
- composition
- prebiotics
- probiotics
- orlistat
- probiotic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 59
- 235000013406 prebiotics Nutrition 0.000 title claims abstract description 56
- 239000006041 probiotic Substances 0.000 title claims abstract description 55
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 55
- AHLBNYSZXLDEJQ-FWEHEUNISA-N orlistat Chemical compound CCCCCCCCCCC[C@H](OC(=O)[C@H](CC(C)C)NC=O)C[C@@H]1OC(=O)[C@H]1CCCCCC AHLBNYSZXLDEJQ-FWEHEUNISA-N 0.000 claims abstract description 58
- 229960001243 orlistat Drugs 0.000 claims abstract description 53
- 241000186016 Bifidobacterium bifidum Species 0.000 claims abstract description 20
- 229940002008 bifidobacterium bifidum Drugs 0.000 claims abstract description 20
- 229920001202 Inulin Polymers 0.000 claims abstract description 17
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims abstract description 17
- 229940029339 inulin Drugs 0.000 claims abstract description 17
- 229920002261 Corn starch Polymers 0.000 claims abstract description 16
- 240000001046 Lactobacillus acidophilus Species 0.000 claims abstract description 16
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 claims abstract description 16
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 16
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 16
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 16
- 239000008120 corn starch Substances 0.000 claims abstract description 16
- 229940039695 lactobacillus acidophilus Drugs 0.000 claims abstract description 16
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 16
- 229920001353 Dextrin Polymers 0.000 claims abstract description 15
- 239000004375 Dextrin Substances 0.000 claims abstract description 15
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims abstract description 15
- 235000019425 dextrin Nutrition 0.000 claims abstract description 15
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims abstract description 15
- 230000000529 probiotic effect Effects 0.000 claims abstract description 14
- 241000894006 Bacteria Species 0.000 claims abstract description 6
- 238000002156 mixing Methods 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 18
- 238000003756 stirring Methods 0.000 claims description 17
- 238000005303 weighing Methods 0.000 claims description 15
- 230000001954 sterilising effect Effects 0.000 claims description 14
- 239000008187 granular material Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 239000002775 capsule Substances 0.000 claims description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims description 6
- 239000000843 powder Substances 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 4
- 239000008194 pharmaceutical composition Substances 0.000 claims description 4
- 230000002708 enhancing effect Effects 0.000 claims description 3
- 235000014655 lactic acid Nutrition 0.000 claims description 3
- 239000004310 lactic acid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 230000004580 weight loss Effects 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 18
- 229920002774 Maltodextrin Polymers 0.000 abstract description 14
- 239000005913 Maltodextrin Substances 0.000 abstract description 14
- 235000003599 food sweetener Nutrition 0.000 abstract description 14
- 229940035034 maltodextrin Drugs 0.000 abstract description 14
- 239000003765 sweetening agent Substances 0.000 abstract description 14
- 206010067484 Adverse reaction Diseases 0.000 abstract description 5
- 230000006838 adverse reaction Effects 0.000 abstract description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 5
- 230000002195 synergetic effect Effects 0.000 abstract description 4
- 229940099112 cornstarch Drugs 0.000 abstract description 2
- 230000006870 function Effects 0.000 abstract description 2
- 230000002496 gastric effect Effects 0.000 abstract description 2
- 230000000968 intestinal effect Effects 0.000 abstract description 2
- 230000001105 regulatory effect Effects 0.000 abstract description 2
- 210000003608 fece Anatomy 0.000 abstract 1
- 235000013376 functional food Nutrition 0.000 abstract 1
- 230000000052 comparative effect Effects 0.000 description 12
- 239000003921 oil Substances 0.000 description 7
- 235000019198 oils Nutrition 0.000 description 7
- 238000004806 packaging method and process Methods 0.000 description 6
- LUEWUZLMQUOBSB-FSKGGBMCSA-N (2s,3s,4s,5s,6r)-2-[(2r,3s,4r,5r,6s)-6-[(2r,3s,4r,5s,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5s,6r)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-4,5-dihydroxy-2-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@@H](OC3[C@H](O[C@@H](O)[C@@H](O)[C@H]3O)CO)[C@@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O LUEWUZLMQUOBSB-FSKGGBMCSA-N 0.000 description 5
- 229920002581 Glucomannan Polymers 0.000 description 5
- 229940046240 glucomannan Drugs 0.000 description 5
- 206010012735 Diarrhoea Diseases 0.000 description 4
- 229940086609 Lipase inhibitor Drugs 0.000 description 4
- 230000037396 body weight Effects 0.000 description 4
- 238000001035 drying Methods 0.000 description 4
- 241001465754 Metazoa Species 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 238000009924 canning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000007873 sieving Methods 0.000 description 2
- -1 tabletting Substances 0.000 description 2
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- 235000013878 L-cysteine Nutrition 0.000 description 1
- 239000004201 L-cysteine Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 229940009289 bifidobacterium lactis Drugs 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical group NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 description 1
- 229940107187 fructooligosaccharide Drugs 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000003871 intestinal function Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 238000005498 polishing Methods 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001603 reducing effect Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
- A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Obesity (AREA)
- Child & Adolescent Psychology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The invention belongs to the field of functional foods, and particularly relates to a composition of probiotics and prebiotics and application thereof. A composition of probiotic bacteria and prebiotics comprises resistant dextrin, inulin, corn starch, maltodextrin, stachyose, lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum, lactobacillus paracasei and sweetener. Compared with similar products in the market, the composition of the probiotics and the prebiotics has the advantages that the proportion is optimized, unpleasant gastrointestinal side effects caused by orlistat taking are reduced, adverse reactions such as oily spots, fat/oily feces and the like are relieved, the synergistic effect is achieved, and the weight-losing effect is enhanced. Meanwhile, the invention also has the functions of regulating the balance of intestinal flora and improving the health of intestinal tracts.
Description
The application is a divisional application with the application date of 2021.05.31 and the application number of 202110599523.2, and the invention is named as 'a composition of probiotics and prebiotics and application thereof'.
Technical Field
The invention belongs to the technical field of microbial preparations, and relates to a composition of probiotics and prebiotics and application thereof.
Background field of the invention
Orlistat is a lipase inhibitor, achieves the purpose of losing weight by inhibiting the absorption of fat by a human body, is a non-central nervous slimming drug, but can generate unpleasant gastrointestinal side effects such as anal oil leakage (oily spot), fat/oily stool, diarrhea and other adverse reactions when people take orlistat.
Prebiotics are non-digestible ingredients in food or feed that selectively stimulate the growth of beneficial bacteria in the gut of a host animal and thus produce beneficial effects on the animal. The supplement of prebiotics can promote the growth and proliferation of self probiotics in the intestinal tract, and then the prebiotics are matched with the ingested exogenous probiotics to promote the proliferation of the probiotics in the intestinal tract, so that the balance of the intestinal flora can be better adjusted, and the intestinal tract health is easy to realize. According to research, some prebiotics also have good adsorption effect on grease. Thus, extending the field of research on prebiotic compositions may better serve humans.
Chinese patent CN110024932A discloses a formula of a black fungus extracted solid beverage for losing weight, improving diarrhea and adjusting flora and a preparation method thereof, wherein the formula comprises prebiotics, namely fructo-oligosaccharide and inulin, and probiotics, namely lactobacillus plantarum and/or lactobacillus acidophilus and/or bifidobacterium lactis. The product described in the patent is applied to the preparation of food or special food or medicine for losing weight or improving diarrhea or adjusting flora. However, the patent does not describe the effect of improving adverse reactions such as anal leakage of oil (oily spots), fat/oily stool, diarrhea, etc., i.e., the adverse reactions brought by orlistat administration cannot be effectively solved.
Chinese patent CN101420951A discloses a pharmaceutical composition comprising a lipase inhibitor and a lipophilic oil absorbent and an oral formulation prepared therefrom. Wherein the lipophilic oil absorbent is capable of adsorbing unabsorbed oil and minimizing side effects of the lipase inhibitor. However, the finished product prepared by the method has complex formula components and higher cost, has no auxiliary orlistat weight-losing effect, and is proved by experiments to have poor oil stain improving effect.
Chinese patent CN1649580A contains pharmaceutical composition of lipase inhibitor and glucomannan, this composition is used for treating and preventing obesity, relieve adverse reaction such as oily spot, fat stool that orlistat causes. However, the glucomannan in the composition does not have the effect of assisting orlistat in enhancing the weight-losing effect, nor has the effect of regulating the intestinal function. Moreover, when the pharmaceutical composition is taken in the invention, the free oil production of 5 volunteers is reduced by at least 50 percent, which shows that the effect is good, the number of the test subjects is small, the evaluation standard is low, and the persuasion is insufficient.
The invention content is as follows:
the first aspect of the present invention aims to overcome the disadvantages of the prior art and to provide a composition of a probiotic and a prebiotic that can be used in conjunction with orlistat.
The second aspect of the invention aims to provide the application of the composition of the probiotics and the prebiotics in the food for assisting the function of orlistat in enhancing the weight-losing efficacy. In order to achieve the above purpose of the present invention, the following technical solutions are adopted:
a composition of probiotic bacteria and prebiotics comprises resistant dextrin, inulin, corn starch, stachyose and lactic acid bacteria.
Further, the probiotics comprise lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei.
Further, said Bifidobacterium bifidum is selected from Bifidobacterium bifidum TMC3115.
Further, the composition also comprises auxiliary materials.
Further, the auxiliary materials comprise a filling agent and a flavoring agent (including a sweetening agent), the addition amount of the auxiliary materials is the conventional addition amount in the field, and the addition of the auxiliary materials meets the national standard on food additives or is pharmaceutically acceptable auxiliary materials.
Further, in order to obtain a better functional effect, the brewing temperature is not higher than 37 ℃; the composition is administered half an hour after meals; if antibiotics are used, the food is eaten after two hours; the usage amount of inulin is less than or equal to 15 g/day.
Further, the composition of the probiotics and the prebiotics comprises the following components in parts by weight:
further, the composition of the probiotics and the prebiotics comprises the following components in parts by weight:
the combination of the probiotics and the prebiotics or the composition thereof comprises the following steps: weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose and auxiliary materials, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, and finally preparing a finished product.
The composition of probiotics and prebiotics can be made into pill, tablet, capsule, powder, granule and oral liquid.
Compared with the traditional method, the technical scheme of the invention has the following progress:
has synergistic effect and can improve weight reducing effect. Orlistat can inhibit fat absorption, the composition has complementary effects when being matched with orlistat, and the weight-reducing curative effect is more remarkable.
The specific implementation mode is as follows:
the following is a further detailed description of the invention in connection with specific preferred embodiments and should not be taken to limit the invention to these specific embodiments. For those skilled in the art to which the present invention pertains, a plurality of simple deductions or substitutions can be made without departing from the concept of the present invention, which should be considered as belonging to the protection scope of the present invention, and the technologies and indexes used in the present invention but not described are the prior arts.
Unless otherwise specifically stated, various raw materials, reagents, instruments, equipment and the like used in the present invention are commercially available or can be prepared by existing methods.
Example 1
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, granulating by a wet method, drying, granulating, and packaging to obtain the granule.
Example 2
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, preparing into granules, and filling into hard capsules to obtain capsules.
Example 3
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, preparing into granules, tabletting, and coating with a film coating to obtain the tablet.
Example 4
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, sieving with a 80-mesh sieve to obtain fine powder, and packaging to obtain the powder.
Example 5
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, adding water, stirring, pelleting on an automatic pelleting machine, polishing, drying in vacuum, packaging and obtaining the pills.
Example 6
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, adding water, stirring, and canning to obtain the oral liquid.
Comparative example 1
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus and lactobacillus paracasei, mixing uniformly, granulating by a wet method, drying, granulating, and packaging to obtain the granule.
Comparative example 2
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription dose of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, then sterilizing, then adding bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, adding water and stirring, and canning to obtain the oral liquid.
Comparative example 3
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, mixing uniformly, granulating by a wet method, drying, granulating, and packaging to obtain the granule.
Comparative example 4
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing the prescription dose of resistant dextrin, corn starch, stachyose, maltodextrin and sweetener, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, sieving with a 80-mesh sieve to obtain fine powder, and packaging to obtain the powder.
Comparative example 5
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing inulin, corn starch, maltodextrin and sweetener according to the prescription, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, preparing into granules, tabletting, and coating with a film coat to obtain the tablet.
Comparative example 6
A composition of probiotics and prebiotics comprises the following components in parts by weight:
the preparation process comprises the following steps:
weighing maltodextrin and sweetener according to the prescription amount, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, preparing into granules, and filling into hard capsules to obtain capsules.
Experimental example 1
Composition of probiotics and prebiotics to assist orlistat in weight loss efficacy in mice drugs: suljia orlistat capsules in 21 capsules, each containing orlistat 0.12g, the manufacturer: shandong New times pharmaceutical Co., ltd.
1 preparation of animal models
4-week-old KM mice, male and female halves, provided by Lunan pharmaceutical laboratory animal center, were fed with high-fat diet (formula of high-fat diet is casein 1kg, L-cysteine 15g, maltodextrin 0.75kg, sucrose 0.35kg, cellulose 0.25kg, soybean oil 0.15kg, lard 1.25 kg). After 10 weeks of feeding, mice weighing less than 60g were eliminated and then administered in groups.
2 grouping and administration
The rats successfully modeled were randomly divided into the following groups according to body weight:
model group: same volume of physiological saline
Orlistat group: 40 mg/(kg.d) orlistat
Orlistat + composition group of probiotics and prebiotics of example 1: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + composition group of probiotics and prebiotics of example 2: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + composition group of probiotics and prebiotics of example 3: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + example 4 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + composition group of probiotics and prebiotics of example 5: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + example 6 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 1 probiotic and prebiotic composition group: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 2 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 3 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 4 probiotic and prebiotic composition group: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 5 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Orlistat + comparative example 6 composition group of probiotics and prebiotics: 40 mg/(kg.d) orlistat +1500 mg/(kg.d)
Each group of 8 animals was fed high fat diet during the dosing period, three times daily gavage, at 6:00, 14:00, 22:00 gavage, continuous for 8 weeks.
3 body weight measurement
The body weight was weighed every 2 weeks starting at 2 weeks after administration and the results of the experiment are detailed in table 1.
TABLE 1 Effect of groups on mouse body weight (unit: g)
* P <0.05 compared to model group; * P <0.01 compared to model group;
# compared to the orlistat group, P <0.05; # compared to orlistat group, P <0.01.
4, experimental results: at week 4, all other groups were significantly different from the model group; all other groups were very significantly different from the model group starting at week 6. At week 6, only orlistat + example 1, orlistat + example 2 and orlistat + example 6 were significantly different from the orlistat group. At week 8, orlistat + example 1 showed very significant differences compared to the orlistat group. The results show that the orlistat and the probiotic and prebiotic composition with the optimized proportion have good synergistic effect when being used for losing weight, and the proper amount of bifidobacterium bifidum TMC3115 added into the probiotic and prebiotic composition and the orlistat also have good synergistic weight-losing effect when being used together. The combined application of orlistat and prebiotic composition or the combination of orlistat and probiotic composition is not different from the effect of using orlistat alone on weight loss, and has no significant difference.
Chinese patent CN1649580A in example 2 the combined use of orlistat and glucomannan does not have a great difference in weight-reducing effect from orlistat alone, and the patent text also shows that there is no interaction between glucomannan and orlistat, i.e. glucomannan and orlistat in the patent do not act synergistically and cannot be used to aid weight-reducing.
Claims (9)
1. A composition of probiotics and prebiotics, wherein the composition comprises resistant dextrin, inulin, corn starch, stachyose and lactic acid bacteria.
2. The probiotic and prebiotic composition of claim 1 wherein the lactic acid bacteria is selected from at least one of the group consisting of Lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum, and Lactobacillus paracasei.
3. The probiotic and prebiotic composition of claim 2 wherein the bifidobacterium bifidum is bifidobacterium bifidum TMC3115.
4. The probiotic and prebiotic composition of claim 1 comprising the following components in parts by weight:
5. the probiotic and prebiotic composition of claim 4 comprising the following components in parts by weight:
6. the probiotic and prebiotic composition according to claim 1, wherein the pharmaceutical composition is selected from the following forms: pill, tablet, capsule, powder, granule or oral liquid.
7. The process for the preparation of a probiotic and prebiotic composition according to any one of claims 1 to 6 comprising the steps of: weighing the formula amount of resistant dextrin, inulin, corn starch, stachyose and auxiliary materials, mixing and stirring, sterilizing, adding lactobacillus plantarum, lactobacillus acidophilus, bifidobacterium bifidum and lactobacillus paracasei, mixing uniformly, and finally preparing a finished product by adopting the prior art according to the requirement.
8. Use of a composition of probiotics and prebiotics according to any one of claims 1 to 7 in the preparation of a food product.
9. The use according to claim 8, wherein the food product assists in enhancing the weight loss efficacy of orlistat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202211459787.9A CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020104861471 | 2020-06-01 | ||
| CN202010486147 | 2020-06-01 | ||
| CN202211459787.9A CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202110599523.2A CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110599523.2A Division CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN115671132A true CN115671132A (en) | 2023-02-03 |
| CN115671132B CN115671132B (en) | 2024-03-15 |
Family
ID=78787331
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211439642.2A Pending CN115737672A (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202211459787.9A Active CN115671132B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
| CN202110599523.2A Active CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202211439642.2A Pending CN115737672A (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110599523.2A Active CN113750113B (en) | 2020-06-01 | 2021-05-31 | Composition of probiotics and prebiotics and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (3) | CN115737672A (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114376235B (en) * | 2022-01-26 | 2024-04-09 | 广州美春堂医药科技有限公司 | Weight-losing probiotics and prebiotic composition for controlling body fat and preparation method thereof |
| CN115154516B (en) * | 2022-08-22 | 2023-09-01 | 合生元（广州）健康产品有限公司 | Composition for improving appetite and/or promoting digestion and absorption and application thereof |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649580A (en) * | 2002-04-26 | 2005-08-03 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition comprising lipase inhibitor and glucomannan |
| US20070010480A1 (en) * | 2003-05-28 | 2007-01-11 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Dietary food items for a weight control or weight loss diet |
| CN110024932A (en) * | 2019-04-29 | 2019-07-19 | 哈尔滨求真生物科技有限公司 | A kind of black fungus extract solid drink formula and preparation method thereof for losing weight, improving diarrhea, adjust flora |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| WO2021073197A1 (en) * | 2019-10-14 | 2021-04-22 | 鲁南制药集团股份有限公司 | Composition containing lactic acid bacteria and use thereof |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101608172B (en) * | 2009-07-24 | 2013-01-23 | 南京华贞生物医药科技有限公司 | Transformant for reducing weight and fat and preparation method thereof |
| BR112015010639A2 (en) * | 2012-11-12 | 2017-07-11 | Biopolis SL | lactobacillus rhamnosus to reduce body fat accumulation |
| CN104630096B (en) * | 2014-12-16 | 2016-08-24 | 河北一然生物科技有限公司 | There is bifidobacterium bifidum TMC3115 and the application thereof of suppression adipose cell |
| CN106072547A (en) * | 2016-06-28 | 2016-11-09 | 张标 | A kind of probiotic powder with fat-reducing and regulation gastrointestinal function |
| CN109072173A (en) * | 2016-09-06 | 2018-12-21 | 深圳华大生命科学研究院 | Clayton Christensen Salmonella (Christensenella intestinihominis) and its application |
| CN107125767B (en) * | 2017-04-28 | 2020-09-29 | 黑龙江大学 | Preparation method and application of bifidobacterium breve, lactobacillus fermentum and lactobacillus plantarum three-bacterium composite micro-particles |
| CN109223833A (en) * | 2017-07-10 | 2019-01-18 | 上海立龙生物科技有限公司 | A kind of probiotic composition of prevention and improvement obesity |
| CN109170909A (en) * | 2018-10-10 | 2019-01-11 | 河北畅然生物科技有限公司 | A kind of compound probiotic and prebiotic compositions and preparation method thereof improving constipation |
| CN109619595A (en) * | 2018-12-27 | 2019-04-16 | 天津活力达生物科技有限公司 | A kind of composition and its application containing profitable probliotics and prebiotics |
| CN110051003A (en) * | 2019-04-24 | 2019-07-26 | 广州能靓生物技术有限公司 | A kind of compound probiotic composition and its application |
| CN110151796B (en) * | 2019-05-09 | 2020-02-04 | 中科宜康（北京）生物科技有限公司 | Probiotics and prebiotics composition capable of forming lean body mass and application thereof |
| CN110447902B (en) * | 2019-09-10 | 2024-02-20 | 广州宏韵医药科技股份有限公司 | Composition with weight-losing effect |
| CN110464808A (en) * | 2019-09-11 | 2019-11-19 | 君维安(武汉)生命科技有限公司 | Weight-reducing and lipid-lowering Chinese medicine prebiotic compositions and its preparation method and application |
| CN110559384A (en) * | 2019-09-11 | 2019-12-13 | 君维安(武汉)生命科技有限公司 | Traditional Chinese medicine prebiotic composition and preparation method and application thereof |
| CN111096416A (en) * | 2019-12-26 | 2020-05-05 | 宁波御坊堂生物科技有限公司 | Diet-depriving composition for weight-losing meal replacement and preparation method thereof |
| CN111053190A (en) * | 2019-12-26 | 2020-04-24 | 宁波御坊堂生物科技有限公司 | Light-weight food composition for weight-losing meal replacement and preparation method thereof |
-
2021
- 2021-05-31 CN CN202211439642.2A patent/CN115737672A/en active Pending
- 2021-05-31 CN CN202211459787.9A patent/CN115671132B/en active Active
- 2021-05-31 CN CN202110599523.2A patent/CN113750113B/en active Active
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1649580A (en) * | 2002-04-26 | 2005-08-03 | 霍夫曼-拉罗奇有限公司 | Pharmaceutical composition comprising lipase inhibitor and glucomannan |
| US20070010480A1 (en) * | 2003-05-28 | 2007-01-11 | Nutrinova Nutrition Specialties & Food Ingredients Gmbh | Dietary food items for a weight control or weight loss diet |
| CN110024932A (en) * | 2019-04-29 | 2019-07-19 | 哈尔滨求真生物科技有限公司 | A kind of black fungus extract solid drink formula and preparation method thereof for losing weight, improving diarrhea, adjust flora |
| CN110150669A (en) * | 2019-04-29 | 2019-08-23 | 河北一然生物科技有限公司 | A kind of probiotic composition and its application suitable for patients with diabetes mellitus |
| WO2021073197A1 (en) * | 2019-10-14 | 2021-04-22 | 鲁南制药集团股份有限公司 | Composition containing lactic acid bacteria and use thereof |
Non-Patent Citations (3)
| Title |
|---|
| 臧凯丽等: "益生菌剂调整肠道疾病人群菌群结构丰度水平的研究", 《食品科学》, vol. 39, no. 13, pages 133 - 143 * |
| 臧凯丽等: "益生菌胞外蛋白与肠道粘膜免疫细胞互作关系的研究进展", 《食品工业科技》, vol. 39, no. 14, pages 346 - 351 * |
| 马微等: "新型减肥药奥利司他的研究进展", 《华西药学杂志》, vol. 24, no. 4, pages 431 - 433 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN115737672A (en) | 2023-03-07 |
| CN113750113B (en) | 2022-12-02 |
| CN113750113A (en) | 2021-12-07 |
| CN115671132B (en) | 2024-03-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6271571B2 (en) | Composition for maintaining intestinal microbiota equilibrium, process for producing the composition, and use of the composition | |
| KR101911205B1 (en) | Composition for defecation inducement and diet and producing method thereof | |
| CN115074274B (en) | Lactic acid bacteria-containing composition and use thereof | |
| AU2007245501B2 (en) | Use of saffron and/or safranal and/or crocin and/or picrocrocin and/or derivatives thereof as a sateity agent for treatment of obesity | |
| CA2628035A1 (en) | Composition for improving intestinal microflora | |
| WO2017130859A1 (en) | Neuronal cell death inhibitor | |
| CN115671132B (en) | Composition of probiotics and prebiotics and application thereof | |
| CN113355255A (en) | Lactobacillus reuteri LM1071 strain and composition comprising culture thereof | |
| JP2816726B2 (en) | Composition for improving intestinal environment | |
| WO2024149132A1 (en) | Probiotic protein multivitamin and preparation method therefor | |
| JP6945888B1 (en) | Composition for improving immune function | |
| JPH09154535A (en) | Natto (fermented soybean)-containing composition | |
| KR20220058176A (en) | Prebiotics composition for improving intestinal microflora | |
| JP2012126700A (en) | Gastrointestinal function promotor | |
| JP7280649B1 (en) | oral composition | |
| JP2003339350A (en) | Diet food | |
| JP7257665B2 (en) | oral composition | |
| TWI815258B (en) | Prebiotic composition and cajanus composition use for adjusting human gut microbiota | |
| US8993639B2 (en) | Compound and method for treatment of gastroesophageal reflux | |
| WO2020179810A1 (en) | Composition for increasing occupancy of faecalibacterium in intestinal flora | |
| JP2003052334A (en) | Diet food | |
| JP2004292355A (en) | Anti-stress agent | |
| WO2023166436A1 (en) | Compositions comprising butyric acid and gluconic acid for the treatment of disorders and syndromes associated with intestinal barrier dysfunctions and dysbiosis | |
| KR0144566B1 (en) | Bifidobacteria growth promoter | |
| WO2022045138A1 (en) | Composition for changing occupancy in intestinal flora of specific genera of bacteria |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |